西陇科学(002584) - 2025 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2025 was ¥1,723,911,446.26, a decrease of 10.93% compared to ¥1,935,429,780.12 in the same period last year[5] - Net profit attributable to shareholders increased by 22.59% to ¥8,638,951.94 from ¥7,046,896.18 year-on-year[5] - The company reported a total of RMB 3,422,374,492.16 in current assets, an increase from RMB 3,287,777,849.87[13] - Total operating revenue decreased to ¥1,723,911,446.26 from ¥1,935,429,780.12, a decline of approximately 10.9% year-over-year[16] - Net profit increased to ¥8,957,870.83 from ¥7,263,074.61, representing a growth of approximately 23.3% year-over-year[17] - The total comprehensive income for the period was ¥8,964,243.79 compared to a loss of ¥67,223,564.84 in the previous period, showing a substantial turnaround[18] Cash Flow - The net cash flow from operating activities surged by 1,474.84% to ¥79,415,487.75, compared to ¥5,042,775.40 in the previous year[5] - Cash inflow from operating activities decreased to ¥1,863,781,431.44 from ¥2,466,064,277.67, a decline of about 24.4% year-over-year[19] - Total cash outflow from operating activities amounted to $1,784,365,943.69, down from $2,461,021,502.27, reflecting improved cash management[20] - The net cash flow from investing activities was -$18,400,711.13, an improvement from -$67,167,888.32, suggesting better investment efficiency[20] - Cash inflow from financing activities was $101,345,585.69, compared to $359,902,261.85 in the previous period, indicating a decrease in financing activities[20] - The net cash flow from financing activities was -$109,739,434.55, a decline from $36,759,763.89, highlighting challenges in financing[20] Assets and Liabilities - The total assets at the end of the reporting period were ¥4,841,141,343.99, reflecting a 2.66% increase from ¥4,715,579,071.58 at the end of the previous year[5] - The total liabilities increased to ¥2,525,063,576.39 from ¥2,409,792,792.73, an increase of about 4.8% year-over-year[14] - The company's total liabilities included accounts payable of RMB 676,587,567.61, up from RMB 615,763,209.95[13] - Contract liabilities rose by 42.05% to ¥62,544,039.68, attributed to an increase in advance payments received compared to the same period last year[7] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 80,499, with the largest shareholder holding 9.65% of the shares[8] - The company's basic earnings per share remained stable at ¥0.01, unchanged from the previous year[5] - Basic and diluted earnings per share remained stable at ¥0.01 for both periods[18] Other Financial Metrics - Deferred tax assets increased by 28.17% to ¥17,774,047.47, primarily due to an increase in recognized deferred tax assets[7] - Other income decreased by 38.93% to ¥8,044,225.65, mainly due to a reduction in government subsidies received during the reporting period[7] - The company reported a significant increase in credit impairment losses, which rose by 77.16% to ¥19,684,170.15, due to an increase in bad debt provisions[7] - Research and development expenses decreased to ¥19,695,576.61 from ¥27,256,625.41, a reduction of approximately 27.8% year-over-year[17] - Other comprehensive income after tax increased to ¥6,372.96 from a loss of ¥74,486,639.45, indicating a significant recovery[18] Compensation Commitments - The company committed to a net profit of no less than RMB 49 million for 2022, RMB 63 million for 2023, and RMB 78 million for 2024 from the acquisition of Aikewei Biotechnology[10] - The company has not yet determined whether it will bear compensation obligations related to the performance commitments of Aikewei Biotechnology[11]